title: PHiD-CV effectiveness against invasive pneumococcal disease caused by serotype 19A.
authors.affiliation: GSK Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: marta.x.moreira@gsk.com.
authors.forename: Marta
authors.initials: M
authors.lastname: Moreira
authors.affiliation: GSK Vaccines Clayton, City of Knowledge, Bldg. 230, Panama.
authors.forename: Javier Nieto
authors.initials: JN
authors.lastname: Guevara
authors.affiliation: GSK, Av. El Dorado No. 69B-45, Piso 9, Corporate Center, Bogota, Colombia.
authors.forename: Diana
authors.initials: D
authors.lastname: Caceres
mesh_terms: D006801:Humans; D010403:Penicillin Resistance; D011008:Pneumococcal Infections / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000145:classification*